Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent
Kim SH, Fechner J (2022)
Publication Type: Journal article, Review article
Publication year: 2022
Journal
Book Volume: 75
Pages Range: 307-315
Journal Issue: 4
DOI: 10.4097/kja.22297
Abstract
Intravenous anesthetic agents such as midazolam, propofol, and ketamine are routinely used to provide anesthesia and sedation. They have been shown to effectively induce and maintain amnesia, sedation, and hypnosis in various patient groups and clinical settings. However, all anesthetic agents have the potential to cause unwanted side effects such as hemodynamic instability, respiratory depression, or slow recovery due to prolonged post-procedural sedation. Remimazolam, a recently approved benzodiazepine for general anesthesia and procedural sedation in Korea, has been successfully used for these purpos-es. To date, inconclusive knowledge has been obtained regarding the use of remimazolam in different patient populations and under various surgical conditions. With respect to the specific pharmacokinetic and pharmacodynamic characteristics of remimazolam, the use of remimazolam is expected to increase providing safe general anesthesia and sedation. This review aims to provide an overview of the basic and clinical pharmacology of remim-azolam and to compare it with midazolam and propofol.
Authors with CRIS profile
Involved external institutions
Korea, Republic of (KR)How to cite
APA:
Kim, S.H., & Fechner, J. (2022). Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent. Korean Journal of Anesthesiology, 75(4), 307-315. https://doi.org/10.4097/kja.22297
MLA:
Kim, Seong Hyop, and Jörg Fechner. "Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent." Korean Journal of Anesthesiology 75.4 (2022): 307-315.
BibTeX: Download